JOURNAL OF CLINICAL LABORATORY ANALYSIS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577755, encodeId=e3a45e77559f, content=就是under review状态啊～一个月还好吧，反正我觉得这个杂志挺好发的～前两天改完了proof，交了版面费（挺贵）～注意这两个操作必须是通讯作者的账号来搞。139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢139****6919暂无昵称 2019-10-05 00:00:00 发表: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, beContent=139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Sat Oct 12 00:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106102, encodeId=d067210610269, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;WB验证;生信 经验分享：2022-11-8 提交 2022-12-2 小修 2022-12-3 修回 2022-12-14 接收 版面费 2970美元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1665584867, createdName=ms4000001963313329, createdTime=Wed Dec 14 22:17:06 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=909589, encodeId=4ac690958919, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：8.3号提交初稿，8.28一审意见回来了，两个评审专家提了语言问题，补伦理，还有讨论要写深入一点。编辑给了大修，建议润色。给了三个月返稿时间。由于本人拖延症严重，一直拖到11.23才提交上去。12.10二审意见回来，给了小修，文献格式修改了一下。第二天就提交了。12.12号收到录用通知了。接下来第三天发邮件来校正稿子，发给出版商了。12.19号出版商给了文章的doi号。接下来就等着缴费了。总体来说，杂志对新颖性和语言要求还是很高的。主编态度很友好。杂志分值今年是1.54。对于很多学生毕业，和员工升职称还是一本不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210225/c40b279f8d9142d98ab14e3bca39069d/664b0252899f44acad9aff5e1ef64c07.jpg, createdBy=ff5a5112139, createdName=ms103769498042547, createdTime=Sun Dec 20 17:00:51 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=925944, encodeId=53e8925944b2, content=我1.24投稿，今天变成了evaluating recommendation，不知道结果会怎么样？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335456455, createdName=ms9000001969583399, createdTime=Sat Feb 20 23:36:49 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218260, encodeId=04f41218260c3, content=状态从received.变为submitted持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7ec2580054, createdName=糖糖12, createdTime=Mon May 09 19:53:31 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117649, encodeId=dd1f211e64982, content=这个杂志居然进预警期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5ad2044621, createdName=ringyin760, createdTime=Sun Mar 05 09:54:11 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=)]

2020-10-20 121bf907m43暂无昵称

审稿速度:1.0 | 投稿命中率:75.0
经验分享：非常高效的杂志
9.18 submitted
10.04 minor revision
10.10 a revision has been submitted
10.17 accept
修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！

167 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577755, encodeId=e3a45e77559f, content=就是under review状态啊～一个月还好吧，反正我觉得这个杂志挺好发的～前两天改完了proof，交了版面费（挺贵）～注意这两个操作必须是通讯作者的账号来搞。139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢139****6919暂无昵称 2019-10-05 00:00:00 发表: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, beContent=139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Sat Oct 12 00:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106102, encodeId=d067210610269, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;WB验证;生信 经验分享：2022-11-8 提交 2022-12-2 小修 2022-12-3 修回 2022-12-14 接收 版面费 2970美元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1665584867, createdName=ms4000001963313329, createdTime=Wed Dec 14 22:17:06 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=909589, encodeId=4ac690958919, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：8.3号提交初稿，8.28一审意见回来了，两个评审专家提了语言问题，补伦理，还有讨论要写深入一点。编辑给了大修，建议润色。给了三个月返稿时间。由于本人拖延症严重，一直拖到11.23才提交上去。12.10二审意见回来，给了小修，文献格式修改了一下。第二天就提交了。12.12号收到录用通知了。接下来第三天发邮件来校正稿子，发给出版商了。12.19号出版商给了文章的doi号。接下来就等着缴费了。总体来说，杂志对新颖性和语言要求还是很高的。主编态度很友好。杂志分值今年是1.54。对于很多学生毕业，和员工升职称还是一本不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210225/c40b279f8d9142d98ab14e3bca39069d/664b0252899f44acad9aff5e1ef64c07.jpg, createdBy=ff5a5112139, createdName=ms103769498042547, createdTime=Sun Dec 20 17:00:51 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=925944, encodeId=53e8925944b2, content=我1.24投稿，今天变成了evaluating recommendation，不知道结果会怎么样？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335456455, createdName=ms9000001969583399, createdTime=Sat Feb 20 23:36:49 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218260, encodeId=04f41218260c3, content=状态从received.变为submitted持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7ec2580054, createdName=糖糖12, createdTime=Mon May 09 19:53:31 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117649, encodeId=dd1f211e64982, content=这个杂志居然进预警期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5ad2044621, createdName=ringyin760, createdTime=Sun Mar 05 09:54:11 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=)]

2019-10-12 胡同串子羊

就是under review状态啊～一个月还好吧，反正我觉得这个杂志挺好发的～前两天改完了proof，交了版面费（挺贵）～注意这两个操作必须是通讯作者的账号来搞。139****6919暂无昵称 2019-10-05 发表::
你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢139****6919暂无昵称 2019-10-05 00:00:00 发表:
你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢

139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢

190 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577755, encodeId=e3a45e77559f, content=就是under review状态啊～一个月还好吧，反正我觉得这个杂志挺好发的～前两天改完了proof，交了版面费（挺贵）～注意这两个操作必须是通讯作者的账号来搞。139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢139****6919暂无昵称 2019-10-05 00:00:00 发表: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, beContent=139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Sat Oct 12 00:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106102, encodeId=d067210610269, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;WB验证;生信 经验分享：2022-11-8 提交 2022-12-2 小修 2022-12-3 修回 2022-12-14 接收 版面费 2970美元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1665584867, createdName=ms4000001963313329, createdTime=Wed Dec 14 22:17:06 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=909589, encodeId=4ac690958919, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：8.3号提交初稿，8.28一审意见回来了，两个评审专家提了语言问题，补伦理，还有讨论要写深入一点。编辑给了大修，建议润色。给了三个月返稿时间。由于本人拖延症严重，一直拖到11.23才提交上去。12.10二审意见回来，给了小修，文献格式修改了一下。第二天就提交了。12.12号收到录用通知了。接下来第三天发邮件来校正稿子，发给出版商了。12.19号出版商给了文章的doi号。接下来就等着缴费了。总体来说，杂志对新颖性和语言要求还是很高的。主编态度很友好。杂志分值今年是1.54。对于很多学生毕业，和员工升职称还是一本不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210225/c40b279f8d9142d98ab14e3bca39069d/664b0252899f44acad9aff5e1ef64c07.jpg, createdBy=ff5a5112139, createdName=ms103769498042547, createdTime=Sun Dec 20 17:00:51 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=925944, encodeId=53e8925944b2, content=我1.24投稿，今天变成了evaluating recommendation，不知道结果会怎么样？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335456455, createdName=ms9000001969583399, createdTime=Sat Feb 20 23:36:49 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218260, encodeId=04f41218260c3, content=状态从received.变为submitted持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7ec2580054, createdName=糖糖12, createdTime=Mon May 09 19:53:31 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117649, encodeId=dd1f211e64982, content=这个杂志居然进预警期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5ad2044621, createdName=ringyin760, createdTime=Sun Mar 05 09:54:11 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=)]

2022-12-14 ms4000001963313329 来自北京

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;WB验证;生信
经验分享：2022-11-8 提交
2022-12-2 小修
2022-12-3 修回
2022-12-14 接收
版面费 2970美元

47 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577755, encodeId=e3a45e77559f, content=就是under review状态啊～一个月还好吧，反正我觉得这个杂志挺好发的～前两天改完了proof，交了版面费（挺贵）～注意这两个操作必须是通讯作者的账号来搞。139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢139****6919暂无昵称 2019-10-05 00:00:00 发表: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, beContent=139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Sat Oct 12 00:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106102, encodeId=d067210610269, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;WB验证;生信 经验分享：2022-11-8 提交 2022-12-2 小修 2022-12-3 修回 2022-12-14 接收 版面费 2970美元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1665584867, createdName=ms4000001963313329, createdTime=Wed Dec 14 22:17:06 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=909589, encodeId=4ac690958919, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：8.3号提交初稿，8.28一审意见回来了，两个评审专家提了语言问题，补伦理，还有讨论要写深入一点。编辑给了大修，建议润色。给了三个月返稿时间。由于本人拖延症严重，一直拖到11.23才提交上去。12.10二审意见回来，给了小修，文献格式修改了一下。第二天就提交了。12.12号收到录用通知了。接下来第三天发邮件来校正稿子，发给出版商了。12.19号出版商给了文章的doi号。接下来就等着缴费了。总体来说，杂志对新颖性和语言要求还是很高的。主编态度很友好。杂志分值今年是1.54。对于很多学生毕业，和员工升职称还是一本不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210225/c40b279f8d9142d98ab14e3bca39069d/664b0252899f44acad9aff5e1ef64c07.jpg, createdBy=ff5a5112139, createdName=ms103769498042547, createdTime=Sun Dec 20 17:00:51 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=925944, encodeId=53e8925944b2, content=我1.24投稿，今天变成了evaluating recommendation，不知道结果会怎么样？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335456455, createdName=ms9000001969583399, createdTime=Sat Feb 20 23:36:49 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218260, encodeId=04f41218260c3, content=状态从received.变为submitted持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7ec2580054, createdName=糖糖12, createdTime=Mon May 09 19:53:31 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117649, encodeId=dd1f211e64982, content=这个杂志居然进预警期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5ad2044621, createdName=ringyin760, createdTime=Sun Mar 05 09:54:11 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=)]

2020-12-20 ms103769498042547

审稿速度:1.0 | 投稿命中率:75.0
经验分享：8.3号提交初稿，8.28一审意见回来了，两个评审专家提了语言问题，补伦理，还有讨论要写深入一点。编辑给了大修，建议润色。给了三个月返稿时间。由于本人拖延症严重，一直拖到11.23才提交上去。12.10二审意见回来，给了小修，文献格式修改了一下。第二天就提交了。12.12号收到录用通知了。接下来第三天发邮件来校正稿子，发给出版商了。12.19号出版商给了文章的doi号。接下来就等着缴费了。总体来说，杂志对新颖性和语言要求还是很高的。主编态度很友好。杂志分值今年是1.54。对于很多学生毕业，和员工升职称还是一本不错的杂志。

190 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577755, encodeId=e3a45e77559f, content=就是under review状态啊～一个月还好吧，反正我觉得这个杂志挺好发的～前两天改完了proof，交了版面费（挺贵）～注意这两个操作必须是通讯作者的账号来搞。139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢139****6919暂无昵称 2019-10-05 00:00:00 发表: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, beContent=139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Sat Oct 12 00:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106102, encodeId=d067210610269, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;WB验证;生信 经验分享：2022-11-8 提交 2022-12-2 小修 2022-12-3 修回 2022-12-14 接收 版面费 2970美元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1665584867, createdName=ms4000001963313329, createdTime=Wed Dec 14 22:17:06 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=909589, encodeId=4ac690958919, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：8.3号提交初稿，8.28一审意见回来了，两个评审专家提了语言问题，补伦理，还有讨论要写深入一点。编辑给了大修，建议润色。给了三个月返稿时间。由于本人拖延症严重，一直拖到11.23才提交上去。12.10二审意见回来，给了小修，文献格式修改了一下。第二天就提交了。12.12号收到录用通知了。接下来第三天发邮件来校正稿子，发给出版商了。12.19号出版商给了文章的doi号。接下来就等着缴费了。总体来说，杂志对新颖性和语言要求还是很高的。主编态度很友好。杂志分值今年是1.54。对于很多学生毕业，和员工升职称还是一本不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210225/c40b279f8d9142d98ab14e3bca39069d/664b0252899f44acad9aff5e1ef64c07.jpg, createdBy=ff5a5112139, createdName=ms103769498042547, createdTime=Sun Dec 20 17:00:51 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=925944, encodeId=53e8925944b2, content=我1.24投稿，今天变成了evaluating recommendation，不知道结果会怎么样？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335456455, createdName=ms9000001969583399, createdTime=Sat Feb 20 23:36:49 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218260, encodeId=04f41218260c3, content=状态从received.变为submitted持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7ec2580054, createdName=糖糖12, createdTime=Mon May 09 19:53:31 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117649, encodeId=dd1f211e64982, content=这个杂志居然进预警期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5ad2044621, createdName=ringyin760, createdTime=Sun Mar 05 09:54:11 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=)]

2021-10-04 heyuan2396

审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0
偏重的研究方向：甲状腺癌
经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。

47 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577755, encodeId=e3a45e77559f, content=就是under review状态啊～一个月还好吧，反正我觉得这个杂志挺好发的～前两天改完了proof，交了版面费（挺贵）～注意这两个操作必须是通讯作者的账号来搞。139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢139****6919暂无昵称 2019-10-05 00:00:00 发表: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, beContent=139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Sat Oct 12 00:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106102, encodeId=d067210610269, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;WB验证;生信 经验分享：2022-11-8 提交 2022-12-2 小修 2022-12-3 修回 2022-12-14 接收 版面费 2970美元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1665584867, createdName=ms4000001963313329, createdTime=Wed Dec 14 22:17:06 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=909589, encodeId=4ac690958919, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：8.3号提交初稿，8.28一审意见回来了，两个评审专家提了语言问题，补伦理，还有讨论要写深入一点。编辑给了大修，建议润色。给了三个月返稿时间。由于本人拖延症严重，一直拖到11.23才提交上去。12.10二审意见回来，给了小修，文献格式修改了一下。第二天就提交了。12.12号收到录用通知了。接下来第三天发邮件来校正稿子，发给出版商了。12.19号出版商给了文章的doi号。接下来就等着缴费了。总体来说，杂志对新颖性和语言要求还是很高的。主编态度很友好。杂志分值今年是1.54。对于很多学生毕业，和员工升职称还是一本不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210225/c40b279f8d9142d98ab14e3bca39069d/664b0252899f44acad9aff5e1ef64c07.jpg, createdBy=ff5a5112139, createdName=ms103769498042547, createdTime=Sun Dec 20 17:00:51 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=925944, encodeId=53e8925944b2, content=我1.24投稿，今天变成了evaluating recommendation，不知道结果会怎么样？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335456455, createdName=ms9000001969583399, createdTime=Sat Feb 20 23:36:49 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218260, encodeId=04f41218260c3, content=状态从received.变为submitted持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7ec2580054, createdName=糖糖12, createdTime=Mon May 09 19:53:31 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117649, encodeId=dd1f211e64982, content=这个杂志居然进预警期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5ad2044621, createdName=ringyin760, createdTime=Sun Mar 05 09:54:11 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=)]

2022-11-30 148999f2m69暂无昵称来自陕西省

偏重的研究方向：生物标记物检测
经验分享：各位大佬，这个杂志Under Review和Under review有区别吗

10 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577755, encodeId=e3a45e77559f, content=就是under review状态啊～一个月还好吧，反正我觉得这个杂志挺好发的～前两天改完了proof，交了版面费（挺贵）～注意这两个操作必须是通讯作者的账号来搞。139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢139****6919暂无昵称 2019-10-05 00:00:00 发表: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, beContent=139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Sat Oct 12 00:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106102, encodeId=d067210610269, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;WB验证;生信 经验分享：2022-11-8 提交 2022-12-2 小修 2022-12-3 修回 2022-12-14 接收 版面费 2970美元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1665584867, createdName=ms4000001963313329, createdTime=Wed Dec 14 22:17:06 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=909589, encodeId=4ac690958919, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：8.3号提交初稿，8.28一审意见回来了，两个评审专家提了语言问题，补伦理，还有讨论要写深入一点。编辑给了大修，建议润色。给了三个月返稿时间。由于本人拖延症严重，一直拖到11.23才提交上去。12.10二审意见回来，给了小修，文献格式修改了一下。第二天就提交了。12.12号收到录用通知了。接下来第三天发邮件来校正稿子，发给出版商了。12.19号出版商给了文章的doi号。接下来就等着缴费了。总体来说，杂志对新颖性和语言要求还是很高的。主编态度很友好。杂志分值今年是1.54。对于很多学生毕业，和员工升职称还是一本不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210225/c40b279f8d9142d98ab14e3bca39069d/664b0252899f44acad9aff5e1ef64c07.jpg, createdBy=ff5a5112139, createdName=ms103769498042547, createdTime=Sun Dec 20 17:00:51 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=925944, encodeId=53e8925944b2, content=我1.24投稿，今天变成了evaluating recommendation，不知道结果会怎么样？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335456455, createdName=ms9000001969583399, createdTime=Sat Feb 20 23:36:49 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218260, encodeId=04f41218260c3, content=状态从received.变为submitted持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7ec2580054, createdName=糖糖12, createdTime=Mon May 09 19:53:31 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117649, encodeId=dd1f211e64982, content=这个杂志居然进预警期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5ad2044621, createdName=ringyin760, createdTime=Sun Mar 05 09:54:11 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=)]

2021-02-20 ms9000001969583399

我1.24投稿，今天变成了evaluating recommendation，不知道结果会怎么样？

82 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577755, encodeId=e3a45e77559f, content=就是under review状态啊～一个月还好吧，反正我觉得这个杂志挺好发的～前两天改完了proof，交了版面费（挺贵）～注意这两个操作必须是通讯作者的账号来搞。139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢139****6919暂无昵称 2019-10-05 00:00:00 发表: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, beContent=139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Sat Oct 12 00:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106102, encodeId=d067210610269, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;WB验证;生信 经验分享：2022-11-8 提交 2022-12-2 小修 2022-12-3 修回 2022-12-14 接收 版面费 2970美元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1665584867, createdName=ms4000001963313329, createdTime=Wed Dec 14 22:17:06 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=909589, encodeId=4ac690958919, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：8.3号提交初稿，8.28一审意见回来了，两个评审专家提了语言问题，补伦理，还有讨论要写深入一点。编辑给了大修，建议润色。给了三个月返稿时间。由于本人拖延症严重，一直拖到11.23才提交上去。12.10二审意见回来，给了小修，文献格式修改了一下。第二天就提交了。12.12号收到录用通知了。接下来第三天发邮件来校正稿子，发给出版商了。12.19号出版商给了文章的doi号。接下来就等着缴费了。总体来说，杂志对新颖性和语言要求还是很高的。主编态度很友好。杂志分值今年是1.54。对于很多学生毕业，和员工升职称还是一本不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210225/c40b279f8d9142d98ab14e3bca39069d/664b0252899f44acad9aff5e1ef64c07.jpg, createdBy=ff5a5112139, createdName=ms103769498042547, createdTime=Sun Dec 20 17:00:51 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=925944, encodeId=53e8925944b2, content=我1.24投稿，今天变成了evaluating recommendation，不知道结果会怎么样？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335456455, createdName=ms9000001969583399, createdTime=Sat Feb 20 23:36:49 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218260, encodeId=04f41218260c3, content=状态从received.变为submitted持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7ec2580054, createdName=糖糖12, createdTime=Mon May 09 19:53:31 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117649, encodeId=dd1f211e64982, content=这个杂志居然进预警期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5ad2044621, createdName=ringyin760, createdTime=Sun Mar 05 09:54:11 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=)]

2022-05-09 糖糖12

状态从received.变为submitted持续多久呢

63 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577755, encodeId=e3a45e77559f, content=就是under review状态啊～一个月还好吧，反正我觉得这个杂志挺好发的～前两天改完了proof，交了版面费（挺贵）～注意这两个操作必须是通讯作者的账号来搞。139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢139****6919暂无昵称 2019-10-05 00:00:00 发表: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, beContent=139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Sat Oct 12 00:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106102, encodeId=d067210610269, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;WB验证;生信 经验分享：2022-11-8 提交 2022-12-2 小修 2022-12-3 修回 2022-12-14 接收 版面费 2970美元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1665584867, createdName=ms4000001963313329, createdTime=Wed Dec 14 22:17:06 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=909589, encodeId=4ac690958919, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：8.3号提交初稿，8.28一审意见回来了，两个评审专家提了语言问题，补伦理，还有讨论要写深入一点。编辑给了大修，建议润色。给了三个月返稿时间。由于本人拖延症严重，一直拖到11.23才提交上去。12.10二审意见回来，给了小修，文献格式修改了一下。第二天就提交了。12.12号收到录用通知了。接下来第三天发邮件来校正稿子，发给出版商了。12.19号出版商给了文章的doi号。接下来就等着缴费了。总体来说，杂志对新颖性和语言要求还是很高的。主编态度很友好。杂志分值今年是1.54。对于很多学生毕业，和员工升职称还是一本不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210225/c40b279f8d9142d98ab14e3bca39069d/664b0252899f44acad9aff5e1ef64c07.jpg, createdBy=ff5a5112139, createdName=ms103769498042547, createdTime=Sun Dec 20 17:00:51 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=925944, encodeId=53e8925944b2, content=我1.24投稿，今天变成了evaluating recommendation，不知道结果会怎么样？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335456455, createdName=ms9000001969583399, createdTime=Sat Feb 20 23:36:49 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218260, encodeId=04f41218260c3, content=状态从received.变为submitted持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7ec2580054, createdName=糖糖12, createdTime=Mon May 09 19:53:31 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117649, encodeId=dd1f211e64982, content=这个杂志居然进预警期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5ad2044621, createdName=ringyin760, createdTime=Sun Mar 05 09:54:11 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=)]

2023-03-05 ringyin760 来自广西

这个杂志居然进预警期刊了

45 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577755, encodeId=e3a45e77559f, content=就是under review状态啊～一个月还好吧，反正我觉得这个杂志挺好发的～前两天改完了proof，交了版面费（挺贵）～注意这两个操作必须是通讯作者的账号来搞。139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢139****6919暂无昵称 2019-10-05 00:00:00 发表: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, beContent=139****6919暂无昵称 2019-10-05 发表:: 你好！你发催稿信的时候，你的文章是什么状态？我的现在是Under review，刚1个月，有点着急！谢谢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Sat Oct 12 00:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106102, encodeId=d067210610269, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;WB验证;生信 经验分享：2022-11-8 提交 2022-12-2 小修 2022-12-3 修回 2022-12-14 接收 版面费 2970美元, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1665584867, createdName=ms4000001963313329, createdTime=Wed Dec 14 22:17:06 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=909589, encodeId=4ac690958919, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：8.3号提交初稿，8.28一审意见回来了，两个评审专家提了语言问题，补伦理，还有讨论要写深入一点。编辑给了大修，建议润色。给了三个月返稿时间。由于本人拖延症严重，一直拖到11.23才提交上去。12.10二审意见回来，给了小修，文献格式修改了一下。第二天就提交了。12.12号收到录用通知了。接下来第三天发邮件来校正稿子，发给出版商了。12.19号出版商给了文章的doi号。接下来就等着缴费了。总体来说，杂志对新颖性和语言要求还是很高的。主编态度很友好。杂志分值今年是1.54。对于很多学生毕业，和员工升职称还是一本不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210225/c40b279f8d9142d98ab14e3bca39069d/664b0252899f44acad9aff5e1ef64c07.jpg, createdBy=ff5a5112139, createdName=ms103769498042547, createdTime=Sun Dec 20 17:00:51 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=925944, encodeId=53e8925944b2, content=我1.24投稿，今天变成了evaluating recommendation，不知道结果会怎么样？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335456455, createdName=ms9000001969583399, createdTime=Sat Feb 20 23:36:49 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218260, encodeId=04f41218260c3, content=状态从received.变为submitted持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7ec2580054, createdName=糖糖12, createdTime=Mon May 09 19:53:31 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117649, encodeId=dd1f211e64982, content=这个杂志居然进预警期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5ad2044621, createdName=ringyin760, createdTime=Sun Mar 05 09:54:11 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=)]

2022-03-18 ms4000000222994216

审稿速度:6.0 | 投稿命中率:75.0
经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤
2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）

44 4

展开4条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务